Anti‐tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards

• Ling Tang,
• Yuanyuan Song,
• Hong Zhang,
• Ruimin Hao,
• Xin Tong,
• Xing Ai,
• Jun Ma,
• Zhimin Yang

Affiliations

Ling Tang

Office of Clinical Trial Management, Center for Drug Evaluation, National Medical Products Administration Beijing P. R. China

Yuanyuan Song

Office of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration Beijing P. R. China

Hong Zhang

Office of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration Beijing P. R. China

Ruimin Hao

Office of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration Beijing P. R. China

Xin Tong

Office of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration Beijing P. R. China

Xing Ai

Office of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration Beijing P. R. China

Jun Ma

Harbin Institute of Hematology and Oncology Harbin Heilongjiang P. R. China

Zhimin Yang

Center for Drug Evaluation, National Medical Products Administration Beijing P. R. China